Hazazi Ali, AlShehah Abdulmajid A, Khan Farhan R, Hakami Mohammed Ageeli, Almarshadi Fahad, Abalkhail Adil, Nassar Somia A, Almasoudi Hassan H, Ali Amer Al, Abu-Alghayth Mohammed H, Kukreti Neelima, Binshaya Abdulkarim S
Department of Pathology and Laboratory Medicine, Security Forces Hospital Program, Riyadh, Saudi Arabia; College of Medicine, Alfaisal University, Riyadh, Kingdom of Saudi Arabia.
Department of Ophthalmology, Security Forces Hospital, Riyadh, Saudi Arabia.
Pathol Res Pract. 2024 Feb;254:155081. doi: 10.1016/j.prp.2023.155081. Epub 2024 Jan 3.
The genomic era has brought about a transformative shift in our comprehension of cancer, unveiling the intricate molecular landscape underlying disease development. Eye cancers (ECs), encompassing diverse malignancies affecting ocular tissues, pose distinctive challenges in diagnosis and management. Long non-coding RNAs (lncRNAs), an emerging category of non-coding RNAs, are pivotal actors in the genomic intricacies of eye cancers. LncRNAs have garnered recognition for their multifaceted roles in gene expression regulation and influence on many cellular processes. Many studies support that the lncRNAs have a role in developing various cancers. Recent investigations have pinpointed specific lncRNAs associated with ECs, including retinoblastoma and uveal melanoma. These lncRNAs exert control over critical pathways governing tumor initiation, progression, and metastasis, endowing them with the ability to function as evaluation, predictive, and therapeutic indicators. The article aims to synthesize the existing information concerning the functions of lncRNAs in ECs, elucidating their regulatory mechanisms and clinical significance. By delving into the lncRNAs' expanding relevance in the modulation of oncogenic and tumor-suppressive networks, we gain a deeper understanding of the molecular complexities intrinsic to these diseases. In our exploration of the genomic intricacies of ECs, lncRNAs introduce a fresh perspective, providing an opportunity to function as clinical and therapeutic indicators, and they also have therapeutic benefits that show promise for advancing the treatment of ECs. This comprehensive review bridges the intricate relationship between lncRNAs and ECs within the context of the genomic era.
基因组时代给我们对癌症的理解带来了变革性的转变，揭示了疾病发展背后复杂的分子格局。眼癌（EC）涵盖影响眼部组织的多种恶性肿瘤，在诊断和治疗方面面临独特挑战。长链非编码RNA（lncRNA）是一类新兴的非编码RNA，是眼癌基因组复杂性中的关键角色。lncRNA因其在基因表达调控中的多方面作用以及对许多细胞过程的影响而受到认可。许多研究支持lncRNA在多种癌症的发生中起作用。最近的研究已经确定了与眼癌相关的特定lncRNA，包括视网膜母细胞瘤和葡萄膜黑色素瘤。这些lncRNA对控制肿瘤发生、进展和转移的关键途径发挥作用，使其能够作为评估、预测和治疗指标。本文旨在综合有关lncRNA在眼癌中功能的现有信息，阐明其调控机制和临床意义。通过深入研究lncRNA在致癌和肿瘤抑制网络调节中日益增加的相关性，我们对这些疾病固有的分子复杂性有了更深入的理解。在我们对眼癌基因组复杂性的探索中，lncRNA引入了一个新的视角，提供了作为临床和治疗指标的机会，并且它们还具有治疗益处，有望推动眼癌的治疗。这篇综述在基因组时代的背景下，架起了lncRNA与眼癌之间的复杂关系。
